Stephens Consulting’s GSK GSK Stock Holding History

Stephens Consulting’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$10.8K	Buy	221 +50	+29%	+$2.33K	﹤0.01%	235
2025 Q3	$7.38K	Sell	171 -372	-69%	-$14.5K	﹤0.01%	252
2025 Q2	$20.9K	Sell	543 -66	-11%	-$2.52K	﹤0.01%	259
2025 Q1	$23.6K	Buy	609 +163	+37%	+$5.97K	0.01%	247
2024 Q4	$15.1K	Buy	446 +275	+161%	+$9.9K	﹤0.01%	306
2024 Q3	$6.99K	Hold	171	–	–	﹤0.01%	369
2024 Q2	$6.58K	Hold	171	–	–	﹤0.01%	379
2024 Q1	$7.33K	Hold	171	–	–	﹤0.01%	338
2023 Q4	$6.34K	Hold	171	–	–	﹤0.01%	356
2023 Q3	$6.2K	Hold	171	–	–	﹤0.01%	358
2023 Q2	$6.09K	Hold	171	–	–	﹤0.01%	361
2023 Q1	$6.08K	Hold	171	–	–	﹤0.01%	374
2022 Q4	$6.01K	Hold	171	–	–	﹤0.01%	356
2022 Q3	$5.03K	Sell	171 -1	-0.6%	-$38	﹤0.01%	404
2022 Q2	$9.36K	Hold	172	–	–	0.01%	334
2022 Q1	$9.37K	Hold	172	–	–	0.01%	364
2021 Q4	$9.48K	Buy	+172	New	+$8.95K	0.01%	406

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Stephens Consulting's GSK Position: Q4 2025 in Review

Stephens Consulting increased its GSK (GSK) stake by 29% in Q4 2025, buying an estimated $2.33K and bringing the position to 221 shares worth $10.8K. The position accounts for ﹤0.01% of the portfolio, ranked #235.

Stephens Consulting first reported a position in GSK in Q4 2021 and has held it in 17 quarters since. The position peaked at $23.6K in Q1 2025. 995 funds tracked by Wall St. Rank hold GSK as of Q4 2025.

Stephens Consulting held 221 shares of GSK worth $10.8K as of Q4 2025.
Stephens Consulting bought 50 GSK shares in Q4 2025, an estimated $2.33K.
GSK made up ﹤0.01% of Stephens Consulting's portfolio in Q4 2025, its #235 holding.
Stephens Consulting first reported a position in GSK in Q4 2021 and has held it in 17 quarters since.
Stephens Consulting's GSK position peaked at $23.6K in Q1 2025.
995 funds tracked by Wall St. Rank held GSK as of Q4 2025.

Based on Stephens Consulting's 13F filing for Q4 2025, filed 13 Jan 2026.